CAC

CAC

CAC was established in Shanghai as a private equity firm focused on technology-enabled businesses across mainland China. The founding team assembled operational and investment experience from prior China venture cycles, structuring the firm to capture the shift from consumer internet toward hard-tech and enterprise-grade innovation. CAC's roots sit in the post-2015 era when China's venture industry began its pivot toward deep tech, AI, and industrial digitization, aligning the firm's mandate with state priorities around technological self-sufficiency. CAC invests across early-stage seed, start-up, and growth rounds, with a strategy that spans venture capital and expansion-stage private equity. The firm targets enterprise software, AI/ML, digital health, and industrial technology, reflecting a thesis built on China's domestic substitution push and healthcare modernization. CAC typically leads or co-leads rounds, taking board seats in portfolio companies and structuring investments through direct equity positions. While specific portfolio names are not publicly disclosed in a consolidated form, the firm's stated focus suggests exposure to sectors where China's public markets have created strong exit pathways for enterprise tech and medtech assets. Geographic concentration remains mainland China, with a secondary lens on cross-border opportunities that connect Chinese innovation to Southeast Asian distribution. The firm maintains a lean Shanghai-based team, typical of mid-market China growth managers that prioritize investment density over headcount scale. CAC does not publicly disclose aggregate AUM or total deployment figures. The firm has not broadcast a dedicated philanthropic vehicle or co-investor club structure, suggesting a focused, partnership-driven LP base rather than a broad syndication model. CAC's structural posture rests on sector concentration — enterprise software and healthcare — in a market where many Chinese GPs remain generalist or consumer-internet anchored. This focus creates a sourcing and diligence edge in two sectors that dominate China's public-market exit pipeline, particularly on the STAR Board and Hong Kong Stock Exchange. The firm's ability to write early-stage through growth checks within the same sector vertical gives it a capital-stacking option that wider-mandate peers cannot replicate without competing against their own portfolio allocations.